Cantor Fitzgerald Lifts Earnings Estimates for Codexis

Codexis, Inc. (NASDAQ:CDXS) – Analysts at Cantor Fitzgerald upped their FY2025 earnings per share (EPS) estimates for Codexis in a research report issued on Tuesday, March 4th. Cantor Fitzgerald analyst K. Kluska now anticipates that the biotechnology company will post earnings per share of ($0.49) for the year, up from their prior estimate of ($0.51). Cantor Fitzgerald currently has a “Overweight” rating and a $11.00 target price on the stock. The consensus estimate for Codexis’ current full-year earnings is ($0.77) per share.

Codexis Stock Performance

NASDAQ:CDXS opened at $2.73 on Thursday. The company has a market cap of $226.15 million, a price-to-earnings ratio of -3.14 and a beta of 2.12. Codexis has a fifty-two week low of $2.48 and a fifty-two week high of $6.08. The company has a debt-to-equity ratio of 0.39, a quick ratio of 3.15 and a current ratio of 3.21. The stock has a fifty day moving average price of $4.42 and a 200-day moving average price of $3.96.

Codexis (NASDAQ:CDXS) last announced its earnings results on Thursday, February 27th. The biotechnology company reported ($0.13) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.04) by ($0.09). Codexis had a negative net margin of 96.35% and a negative return on equity of 71.56%. The business had revenue of $21.46 million during the quarter, compared to the consensus estimate of $27.41 million.

Hedge Funds Weigh In On Codexis

Several hedge funds have recently bought and sold shares of CDXS. Perkins Capital Management Inc. boosted its stake in shares of Codexis by 2.8% in the 3rd quarter. Perkins Capital Management Inc. now owns 164,100 shares of the biotechnology company’s stock valued at $505,000 after purchasing an additional 4,500 shares in the last quarter. GSA Capital Partners LLP grew its position in shares of Codexis by 83.5% during the 3rd quarter. GSA Capital Partners LLP now owns 99,629 shares of the biotechnology company’s stock worth $307,000 after buying an additional 45,337 shares during the period. Intech Investment Management LLC acquired a new stake in Codexis in the third quarter valued at approximately $66,000. FMR LLC lifted its stake in shares of Codexis by 1.2% in the third quarter. FMR LLC now owns 4,497,090 shares of the biotechnology company’s stock valued at $13,851,000 after buying an additional 51,822 shares in the last quarter. Finally, State Street Corp increased its holdings in Codexis by 2.7% during the 3rd quarter. State Street Corp now owns 1,551,411 shares of the biotechnology company’s stock worth $4,778,000 after purchasing an additional 41,480 shares in the last quarter. 78.54% of the stock is owned by institutional investors.

Codexis Company Profile

Codexis, Inc discovers, develops, and sells enzymes and other proteins. The company operates through two segments, Performance Enzymes and Novel Biotherapeutics. It offers biocatalyst products and services. The company also provides biocatalyst screening and protein engineering services. In addition, it offers CodeEvolver, a technology platform, which helps in developing and delivering biocatalysts that perform chemical transformations and enhance the efficiency and productivity of manufacturing processes.